What is tirzepatide used for?

What it is being studied for

• Obesity without diabetes: average weight loss of 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg weekly vs 3.1% on placebo over 72 weeks in 2,539 adults (SURMOUNT-1) — human randomized trial [1]
• Obesity, head-to-head with semaglutide: 20.2% vs 13.7% weight loss over 72 weeks in 751 adults (SURMOUNT-5) — open-label human randomized trial [2]
• Type 2 diabetes vs semaglutide 1 mg: HbA1c (a three-month blood-sugar average) fell 2.01–2.30 points vs 1.86 over 40 weeks in 1,879 patients (SURPASS-2) — open-label human randomized trial [3]
• Prediabetes with obesity: over 176 weeks, type 2 diabetes was diagnosed in 1.3% vs 13.3% on placebo among 1,032 participants — three-year analysis of a human randomized trial [4]
• Obstructive sleep apnoea with obesity: breathing interruptions fell by 25.3 and 29.3 events per hour vs 5.3 and 5.5 on placebo over 52 weeks — two human randomized trials [5]
• Heart failure with preserved ejection fraction and obesity: cardiovascular death or worsening heart failure in 9.9% vs 15.3% on placebo (hazard ratio 0.62) in 731 patients (SUMMIT) — human randomized trial [6]
• Heart outcomes in type 2 diabetes with cardiovascular disease, vs dulaglutide: major cardiovascular events in 12.2% vs 13.1% of 13,165 patients — a randomized trial that showed noninferiority but not superiority (p=0.09) [7]
• Fatty liver disease with scarring (MASH, fibrosis stage F2–F3): resolution without worsening fibrosis in 44–62% vs 10% on placebo over 52 weeks in 190 patients — phase 2 human randomized trial [8]

How it works

1. It is a single peptide that switches on two gut-hormone receptors, GIP and GLP-1 (a “dual incretin agonist”), with a fatty-acid chain attached so one injection lasts a week [9]
2. In cell studies it activated signalling at both receptors, and in mice it increased glucose-dependent insulin release and improved glucose tolerance through both [9]
3. In mice, repeated dosing lowered body weight and food intake more than a GLP-1-only drug did [9]
4. In an early human study of 142 subjects, its blood levels supported once-weekly dosing [9]
5. What sets it apart from semaglutide, its closest approved comparator, is the added GIP action; it produced more weight loss than semaglutide in two head-to-head trials [3][2]. The trial reports do not tie the heart, sleep-apnoea or liver results to a specific mechanism; weight loss is the shared correlate [6][5]

Adverse events reported

• Gastrointestinal effects were the most common, mostly mild to moderate and during dose escalation; 4.3–7.1% stopped for adverse events vs 2.6% on placebo [1]
• Against semaglutide: nausea 17–22% vs 18%, diarrhoea 13–16% vs 12%, vomiting 6–10% vs 8%; low blood sugar (below 54 mg/dL) 0.2–1.7% vs 0.4% [3]
• Heart failure trial: 6.3% stopped for adverse events vs 1.4% on placebo; cardiovascular deaths were numerically higher on tirzepatide (2.2% vs 1.4%, hazard ratio 1.58, confidence interval crossing 1) [6]
• Over three years, gastrointestinal events occurred mostly in the first 20 weeks [4]
• Cardiovascular-outcomes trial vs dulaglutide: overall adverse-event rates were similar, with more gastrointestinal events on tirzepatide [7]
• Head-to-head obesity and liver trials: gastrointestinal events were the most common [2][8]

Forms

Every human trial on this page gave tirzepatide as a once-weekly injection under the skin [1][3]. No human data were found for oral, nasal, under-the-tongue or inhaled forms; oral tirzepatide appears only in animal or laboratory work in PP’s forms inventory, which was not re-checked for this page.

For how injected, oral and nasal peptides compare across compounds, see peptide pills vs nasal sprays vs injections.